Newamsterdam Pharma Company N V (NAMSW)

概要ニュース株価時系列 Financials ディスカッション予測

Relative Volume:

ネットキャッシュフロー:

Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile

Newamsterdam Pharma Company N V

Healthcare (1176)

Biotechnology (678)

31 35 206 2971

Gooimeer 2-35, Naarden

NAMSW's Discussions on Twitter

NAMSW を他の銘柄と比較する

株式	価格	時価総額	収益	当期純利益	現金流量	EPS
NAMSW Newamsterdam Pharma Company N V	8.01	0	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	453.61	117.23B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	669.77	72.75B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	645.06	38.65B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	267.41	34.69B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	114.35	27.45B	3.30B	-501.07M	1.03B	-2.1146

Newamsterdam Pharma Company N V (NAMSW) 最新ニュース

Newamsterdam Pharma Company N V (NAMSW) 財務データ

Newamsterdam Pharma Company N V (NAMSW) の財務データはありません。詳細については、他の銘柄を確認してください。

Newamsterdam Pharma Company N V (NAMSW)

Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile

NAMSW を他の銘柄と比較する

Newamsterdam Pharma Company N V (NAMSW) 最新ニュース

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

NAMS: Strategic Executive Compensation Plan Unveiled138K Shares at $21.36 - StockTitan

Where are the Opportunities in (NAMS) - Stock Traders Daily

Make Informed Decisions with NewAmsterdam Pharma Company NV (NAMS) Stock Updates - The News Heater

Ratios Uncovered: Breaking Down NewAmsterdam Pharma Company NV (NAMS)’s Trailing Twelve Months Metrics - The Dwinnex

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? - AOL

Results from NewAmsterdam Pharma Company NV (NAMS) show risk - US Post News

H.C. Wainwright initates NewAmsterdam Pharma Company NV (NAMS) rating to a Buy - Knox Daily

NewAmsterdam Pharma (NASDAQ:NAMS) Trading 4.1% HigherShould You Buy? - MarketBeat

China Universal Asset Management Co. Ltd. Makes New Investment in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

NAMSWNewAmsterdam Pharma Company N.V. Warrant Latest Stock News & Market Updates - StockTitan

JPMorgan Chase & Co. Increases Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by Moody Aldrich Partners LLC - MarketBeat

How To Trade (NAMSW) - Stock Traders Daily

Newamsterdam pharma CFO sells shares worth $1.5 million - MSN

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap DownTime to Sell? - MarketBeat

Newamsterdam pharma's COO sells $3.1 million in stock - MSN

Newamsterdam pharma CFO sells shares worth $1.5 million By Investing.com - Investing.com Australia

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Bought by JPMorgan Chase & Co. - Defense World

NewAmsterdam Pharma to Present at Guggenheim's SMID Cap Biotech Conference - The Manila Times

NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference - GlobeNewswire

NewAmsterdam Pharma's SWOT analysis: obicetrapib stock shows promise amid trials - MSN

Trend Tracker for (NAMS) - Stock Traders Daily

Royal Bank of Canada Reaffirms “Outperform” Rating for NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

NewAmsterdam Pharma's (NAMS) "Outperform" Rating Reaffirmed at Royal Bank of Canada - MarketBeat

Deep Dive Into NewAmsterdam Pharma Stock: Analyst Perspectives (8 Ratings) - Benzinga

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Barclays PLC - Defense World

Analysts Set NewAmsterdam Pharma (NASDAQ:NAMS) Price Target at $39.80 - Defense World

NewAmsterdam Pharma (NASDAQ:NAMS) Receives $39.80 Consensus Price Target from Analysts - MarketBeat

NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 4.9%What's Next? - MarketBeat

NewAmsterdam Pharma’s (NAMS) “Buy” Rating Reiterated at HC Wainwright - Defense World

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga

14 Best 52-Week High Stocks To Buy According to Analysts - Insider Monkey

NewAmsterdam Pharma Company N.V. (NAMS): Analysts Recommend This 52-Week High Stocks Now - Insider Monkey

NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Buy" Rating from HC Wainwright - MarketBeat

NewAmsterdam Pharma Company N.V. Issues Press Release and Corporate PresentationOn January 10, 2025, NewAmsterdam Pharma Company N.V. filed a Form 8-K with the Securities and Exchange Commission, highlighting significant achievements in 2 - Defense World

NewAmsterdam gears up for obicetrapib regulatory filings By Investing.com - Investing.com Australia

NewAmsterdam gears up for obicetrapib regulatory filings - Investing.com India

NewAmsterdam Pharma Achieves Key Milestones in 2024 - TipRanks

NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities - The Manila Times

NewAmsterdam's Cholesterol Drug Achieves Major Breakthroughs: 33% LDL-C Drop in Phase 3 Trials - StockTitan

Geode Capital Management LLC Purchases 1,399 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

NewAmsterdam Pharma Grants Equity Awards to New Chief People Officer, Key Hires - StockTitan

NewAmsterdam Pharma (NASDAQ:NAMS) Hits New 12-Month HighTime to Buy? - MarketBeat

Newamsterdam Pharma Company N V (NAMSW) 財務データ

収益

当期純利益

現金流量

EPS

NAMSWに似た銘柄